Literature DB >> 3204105

Chlorocarbamate-mustard-linked 1,1,2-triphenylbut-1-enes with a selective antitumor activity on mammary tumors containing estrogen receptors.

M R Schneider1, M L Schuderer.   

Abstract

A 1,1,2-triphenylbut-1-ene with a 4-OH group at one C-1 phenyl ring and a chlorocarbamate mustard moiety at the second C-1 ring (compound 3) was synthesized in order to obtain a "cytotoxic estrogen" with a specific antitumor effect on estrogen-receptor-containing tumors. This compound was tested in comparison to the carrier (compound 1) and a compound (2) having a carbamate mustard group on both C-1 phenyl rings. The estrogen receptor affinity of compound 3 was only about one-quarter lower than that of compound 1, but much higher than that of compound 2. Compounds 2 and 3 showed only partially irreversible binding to the receptor owing to their relatively low alkylating properties. The growth inhibition of the receptor-positive MCF-7 breast cancer cell line by compound 3, but not by compound 1 or 2, was more pronounced than the inhibition of the receptor-negative line MDA. In vivo the hormone-dependent, transplantable mammary tumor MXT M3.2 of the mouse was much better inhibited by compound 3 than its hormone-resistent line MXT OVEX. Compounds 1-3 had no antiestrogenic properties in the mouse, but estrogenic activity was in the order 1 greater than 3 greater than 2. From these results and because the antitumor activity of compound 3 was superior to that of compounds 1 and 2 in the hormone-dependent tumor models, a selective, receptor-mediated cytotoxic effect of compound 3 on estrogen-receptor-positive tumors in obvious.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3204105     DOI: 10.1007/bf00398181

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  8 in total

1.  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.

Authors:  J Karl; R Gust; T Spruss; M R Schneider; H Schönenberger; J Engel; K H Wrobel; F Lux; S T Haeberlin
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

2.  Anticancer agents: N'-(2-chloroethyl)-N'-nitrosocarbamoyl amino acid derivatives of steroid hormones.

Authors:  G Eisenbrand; M Berger; J Fischer; M Schneider; W Zeller; W Tang
Journal:  Cancer Treat Rev       Date:  1987-12       Impact factor: 12.111

3.  Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro.

Authors:  V C Jordan; R Koch; S Mittal; M R Schneider
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.

Authors:  G Leclercq; N Devleeschouwer; J C Heuson
Journal:  J Steroid Biochem       Date:  1983-07       Impact factor: 4.292

5.  Cytotoxic esters of 1,1-bis-(4-hydroxyphenyl)-2-phenyl-but-1-ene with selective antitumor activity against estrogen receptor-containing mammary tumors.

Authors:  M L Schuderer; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties.

Authors:  M R Schneider; E von Angerer; H Schönenberger; R T Michel; H P Fortmeyer
Journal:  J Med Chem       Date:  1982-09       Impact factor: 7.446

7.  Acetoxy substituted 1,1,2-triphenylbut-1-enes: estrogenic, antiestrogenic and mammary tumor inhibiting activity.

Authors:  M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.

Authors:  L L Wei; W F Mangel; B S Katzenellenbogen
Journal:  J Steroid Biochem       Date:  1985-12       Impact factor: 4.292

  8 in total
  1 in total

1.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.